• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Are Fluoroquinolones Truly Associated with Increased Risk of Aortic Dissection?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Recent observational studies have reported an association between fluoroquinolone and increased risk of aortic aneurysm or aortic dissection (AA/AD) | FDA has released a Drug Safety Communication addressing this risk
    • However, previous studies did not consider the role of coexisting infections nor the effects of fluoroquinolones vs other antibiotics
  • Dong et al. (JAMA Intern Med)
    • Estimated the risk of AA/AD associated with infections
    • Assessed the comparative risk of AA/AD associated with fluoroquinolones vs other antibiotics with similar indication profiles

METHODS:

  • Nested case-control study (January 1, 2009, to November 30, 2015)
  • Data sources
    • Nationwide population-based health insurance claims database 
  • Exposures
    • Infections and antibiotic use within a 60-day risk window before the occurrence of AA/AD
  • Study design
    • Every incident case of AA/AD was matched with 10 control individuals based on age, sex, and follow-up duration using risk-set sampling
    • Conditional logistic regression was used to estimate the odds ratios (ORs) comparing infections for which fluoroquinolones are commonly used vs no infection within a 60-day risk window before outcome occurrence | Adjustments made for baseline confounders and concomitant antibiotic use
    • Fluoroquinolones were compared to other antibiotics with similar indication profiles within patients with indicated infections

RESULTS:

  • 28,948 cases | 289,480 matched controls
    • 71.37% male | Mean (SD) age 67.41 (15.03) years
  • There was an association between AA/AD and ‘any indication’ infection
    • OR 1.73 (95% CI, 1.66 to 1.81)
  • However, fluoroquinolones were not associated with an increased AA/AD risk in patients with indicated infections when compared with
    • Combined amoxicillin-clavulanate or combined ampicillin-sulbactam
      • OR 1.01 (95% CI, 0.82 to 1.24)
    • Extended-spectrum cephalosporins
      • OR 0.88 (95% CI, 0.70 to 1.11)
  • Findings did not differ based on subgroup analysis

CONCLUSION:

  • Although fluoroquinolone use was associated with AA/AD, this association was no longer apparent when fluoroquinolones where compared to other antibiotics used for the same indication
  • A recent study by Gopalakrishnan et al. (JAMA Intern Med, 2020) reached similar conclusions
    • Risk of AA/AD was slightly increased with fluoroquinolone use in pneumonia, compared to other antibiotics, but there was no association for patients with urinary tract infections
  • The results of these studies confirm the importance of adjusting for pre-existing infections when assessing antibiotic safety
  • The authors conclude

This study’s results emphasize the importance of considering coexisting infections while examining the safety of antibiotics using real-world data

Concern about AA/AD should not preclude patients with indicated infections from necessary treatment with fluoroquinolones

Learn More – Primary Sources:

Association of Infections and Use of Fluoroquinolones With the Risk of Aortic Aneurysm or Aortic Dissection

Association of Fluoroquinolones With the Risk of Aortic Aneurysm or Aortic Dissection

Observational Study Design Challenges—The Case of Fluoroquinolones and Aortic Disease

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Could Quinolone Exposure Increase Risk to Fetus?
FDA Fluoroquinolone Warning Including Use for UTI Management
Does Antibiotic Use Increase Risk of Spontaneous Abortion?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site